Pharmacovigilance UK & EU 2027
10 March 2027 – 11 March 2027
Sheraton Skyline Hotel London Heathrow, London, United Kingdom
The 44th Pharmacovigilance UK & EU 2027 conference brings together pharmaceutical, biotechnology, CRO and regulatory professionals to exchange practical insights on drug safety. The programme covers artificial intelligence and real-world evidence, patient-centricity, inspection readiness, risk management and minimisation, and the evolving UK and EU regulatory frameworks.
22 sessions · 36 speakers
Organiser (1)
Sponsor (1)
Speakers (36)
- Pav Rishiraj Director, Head of Pharmacovigilance, Ipsen
- Sabine Poltermann IPS Lead – Risk Management, Bristol Myers Squibb
- Tanuja Halady Senior Medical Director, Head of GPS Oncology Group III at Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
- Galina Cordero QPPV,, JSC Farmak
- Khaudeja Bano Vice President Combination Product Quality, Amgen
- Syed Zafeeruddin Global Vigilance Manager & QPPV Mohap UAE, Self-Employed
- Yvonne Nanciu Country Head Pharmacovigilance Germany and Austria (DE-AT), Bayer
- Naomi Litchfield Director Patient Advocacy, Bionical Emas
- Sumit Munjal Global Head of Medical Safety, Otsuka Pharmaceutical Companies Europe
- Rishi Chopra Global Head of Affiliates & Partner Business, Regulatory Affairs & Pharmacovigilance, CSL
- Esraa A. Zoubi GM Technical Consultant for Regulatory and Pricing Affairs, Jordan Food and Drug Administration المؤسسه العامه للغذاء والدواء الأردنيه
- Sanjeev Srivastav Signal Management Lead, BioNTech SE
- Marianne Mounir Senior Global Auditor, Bayer
- John Poustie Head of Consumer Safety Global Operations, Haleon
- Giovanni Furlan Head Medical Safety Operations, Sandoz
- Shaantanu Donde Head of Global Growth & Strategy Team- Global Medical Affairs, Viatris
- Petar Gjorgiev Global Patient Safety Lead, Regeneron
- Luiz Lima Senior Medical Director, Ipsen
- Calvin Johnson Head of International Patient Safety, Bristol Myers Squibb
- Valentina Mancini Head of Drug Safety Europe, QPPV, Shionogi Europe
- Michael Bean Senior Director, BioResearch Regulatory Compliance, Johnson & Johnson
- Shikta Das Scientific Lead Real World Evidence, Oncology, AstraZeneca
- Remco Diab CHEPLAPHARM
- Fabio De Gregorio Vice President, Global Patient Safety, TA Rare Diseases Head, Ipsen
- Sebastian Kloss Global Head RWE, MENARINI Group
- Heinz Weidenthaler Senior Director, Safety Strategy Lead Oncology, BioNTech SE
- Mijal Chavda Senior Director, Global Head of GxP Inspections & GVP Quality, Kyowa Kirin International plc.
- Chetan Shatapathy Executive Director, Patient Safety Oncology and Head ADC Patient Safety, AstraZeneca
- Smrutti Kothari Associate Director, Global Patient Safety. Quality & Compliance, Regeneron
- Judy Barretto Senior Director, Gilead Sciences
- Zoe Conway Head of Portfolio Clinical Safety, Roche
- Jean Kilgour-Christie Sandoz
- Marjan Dzeparoski RA and PV Manager, Faculty of Medical Sciences - Pharmacy
- Krupa Patel Safety Evaluation and Risk Management Director UK, GSK
- Arijit Patra Senior Principal Scientist, UCB
- Zina Sadeq Amicus Therapeutics
Agenda
- Chairperson opening remarks 10 March 2027
- Leading the Charge in Pharmacovigilance: Breaking Down Silos for Patient & Customer Safety 10 March 2027
- FIH study- safety considerations, including role of AI 10 March 2027
- Topic TBC 10 March 2027
- Keynote Panel Discussion – From Adverse Event Reporting to Meaningful Patient Safety: Putting the Patient at the Centre of Modern Pharmacovigilance 10 March 2027
- Solution Provider Presentation 10 March 2027
- Panel Discussion – The Digital Pharmacovigilance Revolution: Harnessing AI, RWE & RWD to Transform Safety Intelligence Across the UK and EU 10 March 2027
- Panel Discussion – The Outsourced PV Model Under the Microscope: Strengthening Oversight, Accountability & Quality Across Global Vendor Networks 10 March 2027
- The Round Table Series – Table 5 – Risk Management (RMP / REMS): Next-Generation Risk Management: Evolving RMP Strategies for Patient Safety 10 March 2027 · Table 5
- The Round Table Series – Table 6 – Quality, Safety & Signal Detection: Ensuring Quality and Safety in PV: Advanced Approaches to Signal Detection and Risk Evaluation 10 March 2027 · Table 6
- The Round Table Series – Table 4 – Regulatory Landscape: Navigating Global PV Regulations: Updates, Expectations, and Future Directions 10 March 2027 · Table 4
- The Round Table Series – Table 3 – Outsourcing & Collaboration: Collaborative Pharmacovigilance: Optimizing Partnerships Across Sponsors, CROs, Sites, and Patients 10 March 2027 · Table 3
- The Round Table Series – Table 2 – Audits & Inspections: Audit-Ready Pharmacovigilance: Inspection Preparedness, Compliance, and Best Practices 10 March 2027 · Table 2
- The Round Table Series – Table 1 – Technology & Innovation: Transforming Pharmacovigilance Through Technology: AI, Analytics, and Real-World Evidence 10 March 2027 · Table 1
- Chairperson opening remarks 11 March 2027
- The Future of Individual Case Safety Reports: Evolving Data Sources, Reporting Standards & Data Quality 11 March 2027
- Panel Discussion – From Signals to Safety Decisions: Advancing Signal Detection, Evaluation & Emerging Risk Identification in Modern Pharmacovigilance 11 March 2027
- Solution Provider Presentation 11 March 2027
- Keynote Panel Discussion – From Risk Identification to Risk Minimisation: Reimagining Pharmacovigilance Risk Management Across the Product Lifecycle 11 March 2027
- Solution Provider Presentation 11 March 2027
- Read, Delete, Forget? Making Risk Communication Worth Opening 11 March 2027
- Panel Discussion – UK & EU Pharmacovigilance in Transition: Navigating Regulatory Change, Divergence & Emerging Compliance Expectations 11 March 2027